S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

NASDAQ:ABUS - Arbutus Biopharma Stock Price, Forecast & News

$2.40
+0.05 (+2.13 %)
(As of 12/11/2019 04:00 PM ET)
Today's Range
$2.26
Now: $2.40
$2.43
50-Day Range
$0.87
MA: $1.54
$2.40
52-Week Range
$0.82
Now: $2.40
$4.78
Volume271,701 shs
Average Volume398,158 shs
Market Capitalization$136.44 million
P/E RatioN/A
Dividend YieldN/A
Beta1.8
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ABUS
CUSIPN/A
Phone604-419-3200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.90 million
Book Value$1.33 per share

Profitability

Net Income$-57,060,000.00
Net Margins-2,416.39%

Miscellaneous

Employees79
Market Cap$136.44 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive ABUS News and Ratings via Email

Sign-up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.


Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Corp (NASDAQ:ABUS) announced its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.22. The biopharmaceutical company earned $3.10 million during the quarter, compared to analysts' expectations of $9.85 million. Arbutus Biopharma had a negative net margin of 2,416.39% and a negative return on equity of 298.87%. View Arbutus Biopharma's Earnings History.

When is Arbutus Biopharma's next earnings date?

Arbutus Biopharma is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Arbutus Biopharma.

What price target have analysts set for ABUS?

3 brokerages have issued twelve-month price objectives for Arbutus Biopharma's stock. Their forecasts range from $3.00 to $5.00. On average, they anticipate Arbutus Biopharma's share price to reach $4.00 in the next year. This suggests a possible upside of 66.7% from the stock's current price. View Analyst Price Targets for Arbutus Biopharma.

What is the consensus analysts' recommendation for Arbutus Biopharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Arbutus Biopharma.

Has Arbutus Biopharma been receiving favorable news coverage?

Headlines about ABUS stock have trended somewhat negative on Wednesday, InfoTrie reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Arbutus Biopharma earned a daily sentiment score of -1.1 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Arbutus Biopharma.

Are investors shorting Arbutus Biopharma?

Arbutus Biopharma saw a increase in short interest during the month of November. As of November 29th, there was short interest totalling 1,120,000 shares, an increase of 55.0% from the November 14th total of 722,500 shares. Based on an average trading volume of 594,700 shares, the short-interest ratio is currently 1.9 days. Currently, 3.0% of the shares of the company are sold short. View Arbutus Biopharma's Current Options Chain.

Who are some of Arbutus Biopharma's key competitors?

What other stocks do shareholders of Arbutus Biopharma own?

Who are Arbutus Biopharma's key executives?

Arbutus Biopharma's management team includes the folowing people:
  • Dr. Mark Joseph Murray, Pres, CEO & Director (Age 70)
  • Mr. David C. Hastings, CFO & Chief Accounting Officer (Age 58)
  • Dr. Gaston Picchio Ph.D., Chief Devel. Officer (Age 56)
  • Dr. Michael J. Sofia, Chief Scientific Officer (Age 61)
  • Dr. Elizabeth Howard, Exec. VP, Gen. Counsel & Chief Compliance Officer (Age 65)

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Millennium Management LLC (0.63%), Tower Research Capital LLC TRC (0.07%) and SG Americas Securities LLC (0.06%). View Institutional Ownership Trends for Arbutus Biopharma.

Which major investors are selling Arbutus Biopharma stock?

ABUS stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC. View Insider Buying and Selling for Arbutus Biopharma.

Which major investors are buying Arbutus Biopharma stock?

ABUS stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC and Tower Research Capital LLC TRC. View Insider Buying and Selling for Arbutus Biopharma.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $2.40.

How big of a company is Arbutus Biopharma?

Arbutus Biopharma has a market capitalization of $136.44 million and generates $5.90 million in revenue each year. The biopharmaceutical company earns $-57,060,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Arbutus Biopharma employs 79 workers across the globe.View Additional Information About Arbutus Biopharma.

What is Arbutus Biopharma's official website?

The official website for Arbutus Biopharma is http://www.arbutusbio.com/.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 100-8900 GLENLYON PARKWAY, BURNABY A1, V5J 5J8. The biopharmaceutical company can be reached via phone at 604-419-3200 or via email at [email protected]


MarketBeat Community Rating for Arbutus Biopharma (NASDAQ ABUS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  355 (Vote Outperform)
Underperform Votes:  273 (Vote Underperform)
Total Votes:  628
MarketBeat's community ratings are surveys of what our community members think about Arbutus Biopharma and other stocks. Vote "Outperform" if you believe ABUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel